In one application of phage display technology, large libraries of antibody fragments displayed on phage particles are used to select antibodies that bind to molecules expressed on the surface of eukaryotic cells. The advantage of this method is that antibodies can be selected against antigens in their native configuration, without the need to purify or express the antigen as a recombinant protein. Moreover, this approach may be used to search for novel membrane molecules expressed by subpopulations of cells that are difficult to address by conventional methods, e.g., small numbers of cells present in heterogeneous mixtures. It has been shown that the isolation of cell-bound phages is compatible with immunofluorescence staining and flow cytometric identification and sorting of cells based on multiparameter analysis. Here, we have employed a semi-synthetic phage display library of human single-chain Fv (scFv) antibody fragments in combination with flow cytometry to isolate antibodies against rare populations of precursor and mature dendritic cells (DCs) present in human peripheral blood. DCs are a phenotypically heterogeneous population of professional antigen presenting cells of bone marrow origin with complex and only partly understood developmental relationships and functions. We have isolated phage antibodies against subpopulations of blood DCs and analyzed the distribution of the target antigens. The results show that these phage antibodies are useful tools to further dissect relationships and function of DCs in healthy and diseased tissues.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0022-1759(99)00140-4 | DOI Listing |
J Virol
January 2025
Research Center for Swine Diseases, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, China.
Unlabelled: Porcine deltacoronavirus (PDCoV) is an enteric pathogen that burdens the global pig industry and is a public health concern. The development of effective antiviral therapies is necessary for the prevention and control of PDCoV, yet to date, there are few studies on the therapeutic potential of PDCoV-neutralizing antibodies. Here, we investigate the therapeutic potential of a novel monoclonal antibody (mAb 4A6) which targets the PDCoV S1 protein and effectively neutralizes PDCoV, both pre- and post-attachment on cells, with IC50 values of 0.
View Article and Find Full Text PDFProtein Sci
February 2025
Department of Biotechnology and Bioengineering, Sandia National Laboratories, Livermore, California, USA.
Engineered monoclonal antibodies have proven to be highly effective therapeutics in recent viral outbreaks. However, despite technical advancements, an ability to rapidly adapt or increase antibody affinity and by extension, therapeutic efficacy, has yet to be fully realized. We endeavored to stand-up such a pipeline using molecular modeling combined with experimental library screening to increase the affinity of F5, a monoclonal antibody with potent neutralizing activity against Venezuelan Equine Encephalitis Virus (VEEV), to recombinant VEEV (IAB) E1E2 antigen.
View Article and Find Full Text PDFRecent Pat Biotechnol
January 2025
Center of Excellence in Recombinant Biopharmaceutical Proteins, Biochemistry and Molecular Biology Department, Theodor Bilharz Research Institute, Giza, Egypt.
Background: poses a considerable global public health challenge. In Egypt, approximately 60% of the inhabitants in the Northern and Eastern areas of the Nile Delta are affected by this parasite, whereas the Southern region experiences a significantly lower infection rate of 6%.
Aim: Construction of an immune phage display Nbs library based on the VHH framework for selecting -specific Nbs for seeking cost-effective, sensitive, and specific diagnostic tools for rapidly detecting mansoni.
Antib Ther
January 2025
Biologics Innovation Institute, Shanghai Jemincare Pharmaceutical Co., Ltd., Lane 535, Huanqiao Road, Pudong New Area, Shanghai 201315, China.
Background: Therapeutic antibody drugs targeting the PD-1 pathway are generally characterized by relatively low response rates and susceptibility to drug resistance during clinical application. Therefore, there is an urgent need for alternative therapeutic strategies to increase the immune response rate. Bispecific antibodies co-targeting PD-1 and PD-L1 may have greater potential to improve the efficacy of the immune checkpoint pathway.
View Article and Find Full Text PDFAm J Respir Cell Mol Biol
January 2025
Wayne State University, Division of Pulmonary, Critical Care and Sleep Medicine, Detroit, Michigan, United States;
Numerous chronic human disorders are associated with immune activation by obscure antigen(s). We identified a novel sarcoidosis-epitope (ChainA) by immunoscreening of a novel T7 phage library and confirmed an abundance of ChainA IgG-antibody in sarcoidosis. We tested whether ChainA epitope elicits immune responses through B-cell activation, plasma cell differentiation and antibody production.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!